65 results on '"Kastelein, John J.P."'
Search Results
2. Can we revive CETP-inhibitors for the prevention of cardiovascular disease?
3. Beyond the Usual Suspects: Expanding on Mutations and Detection for Familial Hypercholesterolemia.
4. Carotid Intima-Media Thickness Progression as Surrogate Marker for Cardiovascular Risk: Meta-Analysis of 119 Clinical Trials Involving 100 667 Patients.
5. Moving Targets: Recent Advances in Lipid-Lowering Therapies.
6. Effect of an siRNA Therapeutic Targeting PCSK9 on Atherogenic Lipoproteins: Prespecified Secondary End Points in ORION 1.
7. Apolipoprotein C-III Levels and Incident Coronary Artery Disease Risk: The EPIC-Norfolk Prospective Population Study.
8. Icosabutate, a Structurally Engineered Fatty Acid, Improves the Cardiovascular Risk Profile in Statin-Treated Patients with Residual Hypertriglyceridemia.
9. Homozygous autosomal dominant hypercholesterolaemia in the Netherlands: prevalence, genotype–phenotype relationship, and clinical outcome.
10. Mutations in STAP1 Are Associated With Autosomal Dominant Hypercholesterolemia.
11. Carotid Intima-Media Thickness in Children With Familial Hypercholesterolemia.
12. Novel Therapies Focused on the High-Density Lipoprotein Particle.
13. Recent failures in antiatherosclerotic drug development.
14. Non- HDL cholesterol vs. Apo B for risk of coronary heart disease in healthy individuals: the EPIC-Norfolk prospective population study.
15. Clinical implications of JUPITER in a contemporary European population: the EPIC-Norfolk prospective population study.
16. From Mutation Identification to Therapy: Discovery and Origins of the First Approved Gene Therapy in the Western World.
17. Identification of a loss-of-function inducible degrader of the low-density lipoprotein receptor variant in individuals with low circulating low-density lipoprotein.
18. C-reactive protein and cholesterol are equally strong predictors of cardiovascular risk and both are important for quality clinical care.
19. Diagnosis and treatment of familial hypercholesterolaemia.
20. ABCA1 mutation carriers with low high-density lipoprotein cholesterol are characterized by a larger atherosclerotic burden.
21. Lipid Oxidation in Carriers of Lecithin.
22. Cardiovascular risk in relation to functionality of sequence variants in the gene coding for the low-density lipoprotein receptor: a study among 29 365 individuals tested for 64 specific low-density lipoprotein-receptor sequence variants.
23. Antisense oligonucleotides for the treatment of dyslipidaemia.
24. Infusion of a Lipid Emulsion in Healthy Men Decreases the Serotonergic Response.
25. Advances in genetics show the need for extending screening strategies for autosomal dominant hypercholesterolaemia.
26. Mipomersen, an apolipoprotein B synthesis inhibitor, lowers low-density lipoprotein cholesterol in high-risk statin-intolerant patients: a randomized, double-blind, placebo-controlled trial.
27. Vascular effects and safety of dalcetrapib in patients with or at risk of coronary heart disease: the dal-VESSEL randomized clinical trial.
28. Association of LDL Cholesterol, Non-HDL Cholesterol, and Apolipoprotein B Levels With Risk of Cardiovascular Events Among Patients Treated With Statins.
29. Genetic variation in APOB, PCSK9, and ANGPTL3 in carriers of pathogenic autosomal dominant hypercholesterolemic mutations with unexpected low LDL-Cl Levels.
30. High prevalence of mutations in LCAT in patients with low HDL cholesterol levels in the Netherlands: Identification and characterization of eight novel mutations.
31. Efficacy of apolipoprotein B synthesis inhibition in subjects with mild-to-moderate hyperlipidaemia.
32. Varespladib: targeting the inflammatory face of atherosclerosis.
33. A frequent variant in the ABCA1 gene is associated with increased coronary heart disease risk and a better response to statin treatment in familial hypercholesterolemia patients.
34. Inflammatory biomarkers, physical activity, waist circumference, and risk of future coronary heart disease in healthy men and women.
35. Dyslipidemia of Mothers With Familial Hypercholesterolemia Deteriorates Lipids in Adult Offspring.
36. Assessment of atherosclerosis: the role of flow-mediated dilatation.
37. C-reactive protein is a mediator of cardiovascular disease.
38. Ezetimibe stimulates faecal neutral sterol excretion depending on abcg8 function in mice
39. Carotid Atherosclerosis Progression in Familial Hypercholesterolemia Patients.
40. Functionality of sequence variants in the genes coding for the low-density lipoprotein receptor and apolipoprotein B in individuals with inherited hypercholesterolemia.
41. Comparison between Gradient Gel Electrophoresis and Nuclear Magnetic Resonance Spectroscopy in Estimating Coronary Heart Disease Risk Associated with LDL and HDL Particle Size.
42. The risk of tendon xanthomas in familial hypercholesterolaemia is influenced by variation in genes of the reverse cholesterol transport pathway and the low-density lipoprotein oxidation pathway.
43. Prolactin Levels and the Risk of Future Coronary Artery Disease in Apparently Healthy Men and Women.
44. Effect of Rimonabant on Progression of Atherosclerosis in Patients With Abdominal Obesity and Coronary Artery Disease.
45. Influence of LDL-receptor mutation type on age at first cardiovascular event in patients with familial hypercholesterolaemia.
46. Adherence to evidence-based statin guidelines reduces the risk of hospitalizations for acute myocardial infarction by 40%: a cohort study.
47. Diagnosing familial hypercholesterolaemia: the relevance of genetic testing.
48. Premature cardiovascular disease in young women with heterozygous familial hypercholesterolemia.
49. Mycophenolate mofetil (MMF): Firing at the atherosclerotic plaque from different angles?
50. Update of the molecular basis of familial hypercholesterolemia in The Netherlands.
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.